About RadioGel
RadioGel is a publicly listed company based in Richland (United States) founded in 2006 by Carlton Cadwell. It operates as a yttrium-90 brachytherapy devices for cancer treatment are developed. RadioGel has raised $725 thousand across 1 funding round. Its chief executive is Mike Korenko. RadioGel offers products and services including RadioGel and IsoPet. Its focus areas include Life Sciences, Oncology, Medical Devices and Therapies. Its legal entity is VIVOS INC. Its competitors include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
RadioGel was established in 2006 in Richland, United States, within the medical device sector focused on oncology. Brachytherapy solutions for cancer treatment are created, including the RadioGel device that employs Yttrium-90 particles delivered through needle injectors. Operations center on device development and therapeutic applications, led by founder Carlton Cadwell and CEO Mike Korenko, serving healthcare needs in radiation therapy.
- Headquarters Richland, United States
- Founders Carlton Cadwell
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website radiogel.com
- Social LinkedIn X
- Legal Name Vivos Inc.
- Annual Revenue$68.38 K (USD)144.25as on Dec 31, 2025
- Net Profit-$3.07 M (USD)-5.35as on Dec 31, 2025
- EBITDA-$3.16 M (USD)-21.51as on Dec 31, 2025
- Total Equity Funding$725K (USD)
in 1 rounds
- Latest Funding Round$725K (USD), Series A
Oct 2018
Products & Services of RadioGel
RadioGel offers a comprehensive portfolio of products and services, including RadioGel and IsoPet.
Provides radiation therapy for solid tumors in humans
Offers cancer treatment for pets using radionuclide therapy
Funding Insights of RadioGel
RadioGel has successfully raised a total of $725K through 1 strategic funding round. The most recent funding activity was a Series A round of $725 thousand completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $725,000
- Total Rounds 1
- Last Round Series A — $725,000
- First Round $725,000
(Oct 2018)
All 1 funding rounds of RadioGel with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2018 | $725,000 | Series A | – | – | – |
People of RadioGel
9 people are tracked at RadioGel (5 in leadership, 4 in board & advisors).
| Name | Role | Group |
|---|---|---|
Carlton Cadwell | Founder | Leadership |
Mike Korenko | CEO & President | Leadership |
Michael Pollack | CFO | Leadership |
Nigel R. Stevenson | Chief Science Officer | Leadership |
David J. Swanberg | Chief Technical Manager | Leadership |
Richard Weller | Advisor | Board & advisors |
Alice Villalobos | Advisor | Board & advisors |
Barry D. Pressman | Advisor | Board & advisors |
Albert S. Denittis | Advisor | Board & advisors |
Complete people profiles for RadioGel
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of RadioGel
RadioGel is a publicly listed company on the OTC with ticker symbol RDGL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onOTC: RDGL
- Listed entityVivos Inc.
- Exchange sectorHealth technology
- ISINUS92858K2042
- Share price$0.05 (+1.75% on the day) · 2026-10-13
- Market capitalisation$24.1M
- EPS (diluted, trailing year)$-0.01
- Volume (last session)385,341
Financials of RadioGel
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $68,380 | -$3.1M | -$3.2M |
| 2024 | $28,000 | -$2.9M | -$2.6M |
| 2023 | $19,500 | -$2.9M | -$2.8M |
| 2022 | $36,500 | -$2.5M | -$2.5M |
| 2021 | $14,890 | -$2.5M | -$2.5M |
Detailed financial statements for RadioGel
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of RadioGel
2 dated milestones of RadioGel across 12 years, from founding to its latest funding, stage changes and deals.
- Founded RadioGel is founded.
- Funding First funding round of $725K.
Competitors of RadioGel
RadioGel has 10 listed competitors in our database, 9 of them funded. They include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of RadioGel
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as RadioGel (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Radiogel
Complete news archive for RadioGel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RadioGel
RadioGel was founded in 2006 and raised its 1st funding round 12 years after it was founded.
RadioGel is headquartered in Richland, United States. It is registered at Richland, Washington, United States.
Mike Korenko is the current CEO of RadioGel.
RadioGel is a funded company, having raised a total of $725K across 1 funding round to date. The company's 1st funding round was a Series A of $725K, raised on Oct 2018.
Annual revenue of RadioGel is $68.38K as on Dec 31, 2025.
RadioGel was established in 2006 in Richland, United States, within the medical device sector focused on oncology. Brachytherapy solutions for cancer treatment are created, including the RadioGel device that employs Yttrium-90 particles delivered through needle injectors. Operations center on device development and therapeutic applications, led by founder Carlton Cadwell and CEO Mike Korenko, serving healthcare needs in radiation therapy.
RadioGel's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
RadioGel offers RadioGel and IsoPet.
Yes, RadioGel is publicly traded on OTC under the ticker symbol RDGL.
RadioGel operates through Vivos Inc.